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Abstract
Over the past decade and a half, advances in our understanding of
the pathogenesis of immune-mediated diseases such as rheuma-
toid arthritis (RA) have translated directly into benefit for patients.
Much of this benefit has arisen through the introduction of targeted
biological therapies. At the same time, technological advances
have made it possible to define, at the cellular and molecular levels,
the key pathways that influence the initiation and persistence of
chronic inflammatory autoimmune reactions. As our understanding
grows, it is likely that this knowledge will be translated into a
second generation of biological therapies that are tailor-made for
the patient. This review summarizes current perspectives on RA
disease pathogenesis, with particular emphasis on what RA T cells
look like, what they are likely to see, and how they contribute to
persistence of the chronic inflammatory response.
Introduction
What is rheumatoid arthritis (RA)? Traditional teaching would
have us believe that RA is one of a cluster of autoimmune
diseases, to be included in the same category as type I
diabetes, autoimmune thyroiditis, and celiac disease. There
are some important distinctions, however. The term ‘RA’,
when used in the clinical context, probably represents a
spectrum of distinct clinical entities (for review [1]). This
spectrum manifests not only at the clinical level - presenting
as a range of specific clinical phenotypes - but also at the
cellular, molecular, and genetic levels. This is best illustrated
by the variations observed in patterns of inflammatory infil-
trates in histological sections of RA synovial tissue, the
patterns of disease expression defined by serological profiles,
and the emerging subsets of patients stratified according to
genotype [1]. Such an approach to disease stratification
means that we are now in a position to redefine subtypes of
disease based on objective laboratory parameters, indepen-
dent of clinical manifestations. By defining disease according
to perturbations in cellular and molecular phenotypes and
genotypes, we should be better placed to predict disease
outcome and to select the most appropriate therapy for our
patients.
Diseases such as RA, but also inflammatory bowel disease
and psoriasis, are better characterized as a group of proto-
typic chronic inflammatory diseases. The most convincing
evidence for such a notion comes directly from the clinic, in
particular the striking clinical responses to anticytokine
biological therapy [2]. Finally, RA is somewhat distinct from
other organ-specific autoimmune diseases in the sense that,
rather than destroying the target tissue, the inflammatory
process stimulates and induces proliferation of synovial
stromal tissues, especially in the early phase of disease [3].
Thus, RA is perhaps better described as the prototype
chronic inflammatory disease, with features of autoimmunity.
These distinctions should be taken into account when
considering pathways of disease pathogenesis, especially
immune-mediated pathways. This review highlights current
concepts of RA pathogenesis, with a specific focus on the
immunobiology of the RA T cell.
What should an RA T cell look like?
If the immunobiology of RA plays by the rules governed by
traditional paradigms of autoimmunity, then we would predict
that RA synovial T cells infiltrating affected synovial joints
would express a cell surface phenotype that is compatible
with prior antigen experience, is indicative of extensive
proliferative activity, is suggestive of clonal expansions of
subsets of antigen-specific T cells, is consistent with enhanced
migratory competence, and favors survival in situ. Current
paradigms of adaptive immunity would also predict
differentiation of T-helper cell subsets along a distinct
effector T-cell lineage, whereas histological analysis of
synovial tissue explants might reveal the presence of T cells
as components of diffuse inflammatory infiltrates, with a
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prevalence of CD4+ over CD8+ T cells, in close association
with antigen-presenting cells (APCs). If RA were to fulfil the
criteria for a bona fide organ-specific autoimmune disease,
then elaboration of T cells derived from synovial tissue
explants should identify T cells that are activated and main-
tained  in vivo by tissue-specific autoantigens derived from
synovium, matrix, bone, or a combination of the three. Finally,
the persistence of the chronic inflammatory process should
predict that there might exist a relative paucity of regulatory
T-cell subsets in terms of either cell number or function. How
do these predictions match up with what we have learnt from
laboratory studies?
What do RA T cells really look like?
The most convincing evidence for the involvement of T cells
in chronic immune activation comes from the analysis of RA
synovial biopsies [4]. In keeping with the spectrum of clinical
entities that we classify as RA, distinct patterns of synovitis
have been identified, suggesting topographical organization
of lymphoid microarchitecture at a cellular level [4-6]. We
now know that this process is directed by expression of
cytokines and chemokines, such as lymphotoxin-α1β2 and B-
lymphocyte chemokine/CXC chemokine ligand (CXCL)13
[7]. Patterns of synovitis include diffuse inflammatory
infiltrates of T cells, B cells, macrophages, and dendritic cells
(about 50%); clusters of lymphoid follicular aggregates
comprising T cells, B cells, and dendritic cells (about 20%);
structures with germinal center (GC)-like reactions (about
25%); and, rarely, granulomatous lesions (<5%; which have
features similar to those of rheumatoid nodules). Of most
interest are those tissues comprising secondary follicles and
GCs, because these are characterized by the presence of
follicular dendritic cells, which are critical components in
follicle formation in the synovium and for perpetuation of
adaptive immunity and autoimmunity [6,7]. Thus, the synovial
microenvironment and spatial relationships between cell
subsets appear optimal for supporting antigen requisition,
storage, processing, and presentation by APCs to T cells.
Data suggest that patterns of inflammatory infiltrate are rela-
tively stable over time and common to tissues from different
joints from the same patient, including unaffected joints,
suggesting that they may reflect true disease variants [6,7].
Furthermore, recent support for this notion comes from a
comparison of RA knee joint synovial tissue from anti-cyclic
citrullinated peptide (CCP) positive and negative patients [8].
That study demonstrated higher numbers of infiltrating
lymphocytes (CD3+, CD8+, CD45RO+, and CXCL12+) asso-
ciated with ectopic GC reactions, less extensive fibrosis, and
a thinner synovial lining layer in the anti-CCP+ subset [8]. It is
noteworthy that the direct contribution of CD8+ T cells to
GC+ follicular dendritic cell networks has previously been
demonstrated [9,10]. The anti-CCP+ associated synovial
phenotype is also associated with more radiographic damage
[8]. Emerging data have uncovered a gene expression profile
for GC+ synovial tissue (CD21L+), which complements
immunohistochemical analysis, characterized by elevated
expression of CXCL13, CXCL12, CC chemokine ligand
(CCL)19, CCL21, CXC chemokine receptor (CXCR)4,
CXCR5 and CC chemokine receptor (CCR)7 [11]. In this
study, Gene Ontology pathway analysis suggested that many
pathways active in T cells, including JAK/STAT (Janus kinase/
signal transducer and activator of transcription), T-cell
receptor (TCR), IL-2R, IL-7R, and co-stimulatory signalling
pathways are important features that may promote the cellular
interactions that are required to support the organization of
these tertiary lymphoid structures.
What is the phenotype of RA T cells at the cellular level?
There are a number of distinguishing features. First, synovial
T cells express an extensive array of cell surface antigens that
reflect prior antigen experience (Figure 1). Principle among
these are markers of effector memory cells, including the
expression of specific chemokine receptors and integrins.
The profile of chemokine receptors suggests that there is an
element of selective trafficking of T-cell subsets in response
to local production of chemoattractants by synovial stroma.
Aging is an important risk factor for RA. How does aging
manifest itself at the cellular level? The immune system of
patients with RA, including those developing the disease at a
relatively early age, exhibit features of premature aging, as
determined by accelerated erosion of telomeres, which are
repetitive DNA sequences that cap the ends of chromo-
somes that are lost with cell replication [12]; loss of telomere
length provides an estimate of the number of completed cell
cycles. In RA this process of telomere erosion is found in
both the naïve and memory T-cell compartments, which can-
not therefore be accounted for exclusively by a specific
antigen-driven response. The data suggest an ongoing
process of replicative stress that occurs very early or that may
even predate disease onset. It could arise in part through
reduced generation of new thymic emigrants and/or homeo-
static expansion of the peripheral naïve T-cell repertoire to
environmental stimuli (cytokines or cognate antigen), based
on enumeration of TCR excision circles [12,13]. Nonetheless,
the aging phenotype is not confined to the T-cell compart-
ment, because telomere shortening has been documented in
hematopoietic stem cells, which may explain the features of
senescence in both granulocyte and B-cell compartments. Of
particular interest was the finding of an association between
human leukocyte antigen (HLA)-DR4 status and premature
telomere erosion in healthy donors as well as in patients with
RA, in spite of high telomerase repair activity [14]. These data
provide interesting, if still poorly understood, insights into the
genetic determinants of immune senescence in RA. They also
define a molecular basis for impaired T-cell responsiveness
characteristic of RA, given the close relationship between
telomere erosion and growth arrest.
As mentioned above, the synovial microenvironment provides
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responses. These cellular interactions, combined with an
abundance of inflammatory cytokines and reactive oxygen
intermediates in a hypoxic setting, are probably responsible
for imposing distinct characteristics on synovial T cells.
Specific characteristics of such cells include an intrinsic
resistance to apoptosis in vivo [15]; loss of expression of
CD25, CD28, CD27, CD40L, and the invariant TCR subunit
TCR-ζ [16-18]; enhanced expression of inflammatory
cytokines such as IFN-γ and tumor necrosis factor (TNF)-α
[19]; and expression of CCR4, CCR5, CXCR3, and CXCR5
[20]. Expansion of CD4+CD28null T cells is of interest
because it has been found to correlate with systemic co-
morbidities associated with severe RA, such as vasculitis and
acute coronary syndrome [21,22]. Although this terminally
differentiated CD28null subset may become relatively
independent of co-stimulation through CD80/CD86 engage-
ment, co-stimulation through other pathways such as OX40
may compensate [23]. Indeed, the acquisition of a distinct
gene expression program resembling that of natural killer
(NK) cells, including expression of the activating NK cell
receptors NKG2D and KIR2DS2, and acquisition of DAP10
and DAP12 adaptor proteins for signalling, may explain how
these cells are such potent producers of IFN-γ [24,25].
Synovial T cells can receive signals in situ, because the
counter-ligands for NKG2D, major histocompatibility complex
(MHC) class I chain related (MIC)A and MICB, are expressed
on synovial fibroblasts [26].
In summary, an RA synovial T cell is ideally equipped to
survive in situ through interactions with APCs, macrophages,
B cells, and stromal elements. However, RA T cells are likely
to depend for their effector function on a more promiscuous
range of stimuli, besides cognate antigen presented by MHC
class II molecules. Indeed, aberrant or excessive pathways of
costimulation may permit the T cell to respond to low-affinity
self peptides in the periphery, in spite of both inherited and
acquired defects in TCR signaling.
What do RA T cells see?
Classical paradigms of autoimmunity state that tissue
specificity is determined largely by recognition of tissue-
specific self antigens by autoreactive T and B cells. In the
past there was much enthusiasm for the idea that RA was
driven by joint-specific antigens, for instance type II collagen,
the cartilage protein HCgp-39, and proteoglycans such as
aggrecan, especially because these antigens were inducers
of autoimmune arthritis in appropriate strains of rodent
[27-29]. At the same time, antigens such as heat shock
proteins and BiP (immunoglobulin binding protein) have also
been suggested to be autoantigenic targets [30,31]. These
are ubiquitous proteins expressed at high levels, which are
certainly not tissue specific. It should follow from this para-
digm that in RA it should be possible to detect expansions of
specific clones that express distinct TCRB gene recombi-
nations that are indicative of antigen drive.
Available online http://arthritis-research.com/supplements/10/S1/S1
Figure 1
The phenotype of RA synovial T cells. The schematic depicts examples of cell surface antigens and receptors that confer distinct phenotypes
according to antigen experience, differentiation, and acquisition of memory, migratory competence, terminal differentiation and immune
senescence, and effector function. CCR, CC chemokine receptor; CX3CR, CX3C chemokine receptor; CXCR, CXC chemokine receptor; LFA,
lymphocyte function-associated antigen; LT, lymphotoxin; mTNF, membrane-associated tumor necrosis factor; NK, natural killer; RA, rheumatoid
arthritis; RANKL, receptor activator for nuclear factor-κB ligand; TCR, T-cell receptor; TNFR, tumor necrosis factor receptor; VLA, very late antigen.The aberrations in the TCR repertoire are perhaps best
understood within the context of aging. Thus, as thymic
function declines with age, homeostatic proliferation of naïve
peripheral T cells is required to ‘fill the space’ - that is, to
undertake the task of T-cell generation. As a consequence of
aging, which is accelerated in RA [12], large clonal expan-
sions of T cells are observed [32]. These expansions are
global, affecting both CD4+ and CD8+ subsets, as well as
naïve and memory T-cell populations. Because the process of
homeostatic proliferation is dependent on the recognition by
TCRs of complexes of MHC and self peptide, it will inevitably
lead to the selection of higher affinity autoreactive TCRs with
the capacity to compensate for the functional, proliferative
defects of senescent T cells [33]. Accordingly, there is pro-
found repertoire contraction associated with a lack of
diversity. Indeed, by the age of 40 to 50 years, patients with
RA have already lost 90% of their available TCR repertoires,
whereas the naïve repertoire has expanded 10-fold to fill the
space [16,34-36].
Whereas the expression of distinct HLA-DR molecules can
play an important role in repertoire development through loss
of diversity and contraction of T-cell repertoires in both CD4+
and CD8+ T-cell compartments, as discussed above, there
are also data pointing to antigen-independent pathways of
activation. Thus, both naïve and memory T cells may pro-
liferate and differentiate in response to the inflammatory
milieu into effector T-cell populations with specific cell
surface phenotypes and functional properties, including cyto-
kine expression, cell contact dependent activation of mono-
cytes, and B-cell help [37]. This pathway can be reproduced
in vitro using IL-2, IL-6, and TNF-α, and would account for the
dilution of TCR excision circles in the CD45RA+ naïve
compartment in patients with RA [13].
What MHC/peptide complexes might these T cells see? In
RA we know that T cells see the ‘shared epitope’, a stretch of
DRβ chain α-helix sequence exposed to the TCR encoded by
RA disease associated HLA-DRB1 alleles [38]. We also
know from recent genetic and epidemiological studies that
carrying shared epitope positive alleles is a risk factor not so
much for RA but for immunity to citrullinated proteins [39],
arising through post-translational conversion of arginine
residues to citrulline, which is catalyzed by a family of
enzymes known as peptidyl-arginyl deiminases (PADs) [40].
This manifests as the presence of autoantibodies to
citrullinated protein antigens [41]. Because these are IgG
autoantibodies, it can be inferred that these responses come
about as a consequence of T-cell recognition of related T-cell
epitopes and T-cell help for B-cell antibody production. The
precise T-cell determinants are still being defined, but there
are studies that suggest that T cells may recognize citrulli-
nated peptide epitopes. For example, studies in HLA-DR4
transgenic mice demonstrate a requirement for deimination to
generate immunogenic peptides from a range of candidate
antigens, through the conversion of an epitope with arginine
at P4 that binds poorly to HLA-DR4, to an epitope with
citrulline with more favorable binding kinetics [42]. These
important observations provide a molecular basis for the
association between HLA-DRB1 and anti-citrulline immunity.
The anti-CCP2 test is a robust diagnostic screening tool for
anti-citrulline immunity that is now established in clinical
practice, but the CCP2 antigen is not an autoantigen per se.
Emerging data have defined reproducible autoantibody
responses to citrullinated fibrin, vimentin, α-enolase, histones,
and collagen II [43]. We can speculate that T cells from
patients with RA might therefore see at least a subset of
these antigens. Consistent with this notion is the observation
that autoantibody responses to these specific antigens are
also found in patients who carry ‘at risk’ HLA-DRB1 alleles
[39]. For example, anti-calpastatin immunity is associated with
HLA-DRB1*0404 [44], whereas anti-citrullinated α-enolase
antibody responses are associated with HLA-DRB1*0401
and *0404 (Venables P, Lundberg K, personal communi-
cation). Finally, the generation of a specific monoclonal
antibody that recognizes the immunodominant epitope of
HCgp-39 in a complex bound to HLA-DR4 has made it
possible to demonstrate in situ the presence of MHC II-
peptide complexes in the inflamed RA synovial joint [45]. This
observation would be entirely in keeping with previous
studies demonstrating through autologous mixed lymphocyte
reactions the capacity for synovial APCs to present endo-
genous antigenic peptides to T cells [46].
Multiple T-cell effector pathways contribute
to the chronic inflammatory process
By convention, it is acknowledged that cytokines secreted by
lineage specific T-helper (Th) cells provide the ‘flavor’ of the
effector phase of cell-mediated immunity. In RA many studies
have provided evidence for a Th1 bias, with the cytokine
profile expressed by synovial Th effector cells derived from
patients with established disease dominated by expression of
IFN-γ and TNF, but also IL-10 (for review [47]). Expression of
IL-2, IL-4, IL-5, and IL-13 is low or absent. This contrasts with
the profile of cytokines expressed by synovial T cells and
stromal cells very early in disease, which is dominated by IL-2,
IL-4, IL-13, IL-17, IL-15, basic fibroblast growth factor, and
epidermal growth factor [48]. The mechanisms underlying
this transition are unclear, although reported data have led to
the proposal that there is an intrinsic defect in Th2
differentiation that is explained in part by allelic variants of the
IL-4R, which attenuate activation of STAT6 and induction of
GATA-binding protein 3 [49], both of which are requisites for
commitment to Th2 cell lineage differentiation.
The recent excitement following the identification of a third Th
cell subset, characterized by the expression of IL-17A and IL-
17F (hence termed Th17), as well as IL-22, IL-21 and TNF,
has raised the possibility that Th17 cells may be an important
effector T-cell subset in diseases such as RA, multiple sclero-
sis, and inflammatory bowel disease [50]. Much of the
Arthritis Research & Therapy    Vol 10 Suppl 1 Cope
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of IL-17, IL-17RA, and IL-17RC has been described in RA
synovial tissue and juxta-articular bone by immunohisto-
chemistry [51,52], and IL-17 protein production has been
detected in synovial fluid and culture supernatants of synovial
mononuclear cell explants [48,53]. Indeed, the cytokine milieu
in the joint, with IL-1β, IL-6, and IL-23 in particular, would
certainly support Th17 differentiation. What is unclear is the
precise phenotype of fully differentiated Th17 cells, because -
unlike murine Th17 cells - IL-17+IFN-γ+ cells occur in humans.
Nonetheless, IL-17 is a strong candidate effector cytokine
that probably contributes to the pathogenic features of
established disease, such as the following [54]: induction of
TNF, IL-1, IL-6, and CCL20; synergistic actions with TNF and
IL-1; and - through stimulation of stromal cells, macrophages,
osteoblasts and chondrocytes - promotion of cartilage and
bone destruction. Recent studies have demonstrated low
frequencies of CD4+CD45RO+ T cells expressing IL-17 and
TNF-α, when compared with corresponding peripheral blood
T cells, with their Th1 counterparts being more abundant
[55]. More data are therefore required to establish the
contribution that this subset makes to early and established
phases of the disease.
The spatial context of chronically activated T cells within the
inflamed synovium is important. This has led investigators to
explore the consequences of cell-to-cell interactions, and to
uncover robust induction of monocyte-derived inflammatory
cytokines, chemokines, and matrix metalloproteinases upon
contact with activated T cells [56-58]. The receptor-ligand
pairs involved in these interactions are likely to be numerous,
but integrin and membrane TNF-dependent signaling appear
to have been demonstrated consistently [59], and the
reciprocal interactions between NKG2D and its ligands
MICA and MICB may well contribute to the persistence of
autoreactive T cells within the joint [26], as suggested above.
Whereas the survival of T cells may also be supported
through stromal cell derived type I IFNs [15], reciprocal inter-
actions are also important because T cells downregulate
collagen synthesis by fibroblasts, and are potent inducers of
fibroblast-derived IL-6, prostaglandin E2, chemokines such as
CXCL12, CXCL16 and CCL20, and matrix metalloproteinases
[60-62]. Joint and bone matrix destruction is also induced in
part through RANKL (receptor activator for nuclear factor-κB
ligand)-positive T cells that promote bone erosion through
activation and differentiation of osteoclast precursors [63].
Examples of these cellular interactions are shown in Figure 2.
Why do effector T-cell responses persist?
A major challenge to our understanding of the pathogenesis
of immune-mediated diseases is to elucidate why pathways
of peripheral tolerance might fail. To this end, efforts have
been invested in evaluating the number and function of
regulatory cell subsets, in order to test the hypothesis that at
sites of synovial inflammation there may be defects in path-
ways of peripheral tolerance. Studies have been thwarted to
an extent because until recently the enumeration of subsets
of naturally occurring regulatory T cells was based purely on
CD4 and nonselective high level expression of the T-cell
activation antigen CD25 (hereafter referred to as regulatory
T cells [Tregs]). Even the inclusion of Foxp3 into the
phenotyping armamentarium has not solved the problem,
because this master transcription factor, which plays a
central role in the function of Tregs [64], is also induced upon
TCR engagement of CD4+CD25- T cells [65]. Furthermore,
there remains controversy as to whether there are genuine
defects in the numbers of circulating Tregs in RA. This may
Available online http://arthritis-research.com/supplements/10/S1/S1
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Figure 2
Cell contact-dependent effector function. Spatial and temporal
organization of synovial inflammatory infiltrates favor cell contact-
dependent effector responses between T cells, B cells, macrophages,
and resident stromal cells and adipocytes. The extent to which Tregs
influence these effector pathways is presently unclear. ADAM, a
disintegrin and metalloprotease; ADAM TS, ADAM with
ThromboSpondin-like motifs; FLS, fibroblast-like synoviocytes;
GM-CSF, granulocyte macrophage colony-stimulating factor; HMGB1,
high-mobility group box-1 proteins; IL, interleukin; M-CSF, macrophage
colony-stimulating factor; MΦ, macrophage; MMP, matrix
metalloproteinase; PG, prostaglandin; RANKL, receptor activator for
nuclear factor-κB ligand; TCR, T-cell receptor; Teff, effector T cell; TNF,
tumor necrosis factor; Treg, T regulatory cell; VEGF, vascular
endothelial growth factor.have as much to do with their selective migration and
accumulation in synovial joints compared with peripheral
blood [66], given that Tregs are known to express CXCR4,
CCR4 and CCR8, and a phenotype commensurate with fully
differentiated CD45RO+HLA-DR+CD69+CD62L- T cells,
besides the Treg markers CTLA4 (cytotoxic T-lymphocyte
antigen 4) and GITR (glucocorticoid-induced TNF receptor)
[67]. Whether the inflammatory milieu influences their survival
and function remains a topic of great debate. This is because,
despite expression of transforming growth factor-β, which
might promote the expression and function of Treg subsets,
inflammatory cytokines such as IL-7, IL-15, and TNF have
been shown to suppress Treg activity [68]. One study repor-
ted that high levels of TNF downregulate Foxp3 expression
[69], whereas a second proposed that TNF may attenuate the
generation of adaptive or inducible Tregs in vitro and in vivo
[70]. A third study proposed that, cell for cell, there did not
appear to be a consistent intrinsic defect of RA synovial Treg
suppressor function, but rather synovial effector T cells might
acquire resistance to regulation by Tregs [71]. This concept
is in keeping with recent reports of synovial T cells being
resistant to the immunosuppressive effects of indoleamine
2,3-dioxygenase [72]. How this state of refractoriness comes
about is a key question and requires further investigation.
A recent study of Tregs in the KRN serum transfer model of
autoimmune arthritis demonstrated that more than 40% of
CD4+ T cells were CD25+Foxp3+ in the synovial fluid of either
arthritic KRN mice or of C57BL/6 mice 14 days after injection
with arthritogenic serum, indicating preferential recruitment of
Tregs to inflamed joints, rather than local expansion [73].
When the scurfy loss-of-function Foxp3 mutant was crossed
onto the KRN background, onset of arthritis was faster and
more aggressive. Unexpectedly, the spectrum of affected
joints changed to include joints that were normally clinically
unaffected, including the hip, shoulder, and tempero-
mandibular joint. The authors of this study raise the intriguing
possibility that Tregs actively suppress lymphoid and
nonlymphoid effector cells, actively protecting larger, proximal
joints and rendering them refractory to arthritis. Thus,
pathways of peripheral tolerance appear to be operational in
chronic inflammatory disease, but are clearly insufficient for
resolution of the autoimmune response.
Inherited factors and T-cell-mediated
immunity in RA
What has the immunogenetics of RA taught us about disease
pathogenesis? We have acknowledged the contribution of
the HLA-DRB1 locus for decades, but we have only relatively
recently learnt to appreciate that RA-associated HLA-DR
molecules are not disease susceptibility alleles, but rather are
risk factors for immunity to citrullinated antigens and for
accelerated telomere erosion [14,39]. Using a candidate
gene approach, investigators have identified other disease-
associated single nucleotide polymorphisms that would be
expected to influence T-cell activation, either by modifying
expression of HLA-DR (MHC2TA) [74], predisposing the
host to increased levels of the citrullinating PAD enzymes
Arthritis Research & Therapy    Vol 10 Suppl 1 Cope
Page 6 of 10
(page number not for citation purposes)
Figure 3
Pathway biology: the impact of RA-associated allelic variants. Multiple single nucleotide polymorphisms may contribute to the disease-prone state
through subtle modifications in antigen presentation (‘single input’) and T-cell antigen receptor responsiveness (‘signal output’). It is proposed that
these variants may influence multiple pathways of T-cell activation, differentiation, and effector function. DC, dendritic cell; RA, rheumatoid arthritis;
TCR, T-cell receptor; Teff, effector T cell; Th, T-helper cell.(PADI4) [75], or by perturbing intracellular signals, which
serve to regulate TCR signal transduction (CTLA4 and PD1)
or its downstream consequences (STAT4) [76-78]. RA-asso-
ciated allelic variants that would have an impact on pathways
of T-cell activation are shown in Figure 3.
Perhaps the allelic variant that has received the most
attention is the 1858T mutation of the PTPN22 gene [79],
which encodes a hematopoietic protein tyrosine phosphatase
called Lyp, whose homolog in the mouse (called PEP) is a
potent negative regulator of TCR signaling. Lyp is thought to
switch off TCR signaling by dephosphorylating tyrosine
residues in a range of substrates, including ZAP-70, CD3ε,
TCR-ζ, Vav, and src kinases [80]. Targeting of the src kinase
Lck arises through direct protein-protein associations
between a complex of Lyp and the tyrosine kinase Csk
(through the P1 domain of Lyp and the SH3 domain of the
tyrosine kinase Csk) and Lck. Although the Lyp R620W
mutation is thought to reduce this association [79], the
disease-associated variant is in fact a gain-of-function
phosphatase mutant that further attenuates TCR signaling
[81]. Defining how this contributes to autoimmunity is crucial
because this same mutant has been found to be associated
with a  wide range of autoimmune syndromes, including
systemic lupus erythematosus, autoimmune thyroiditis, Grave’s
disease, and type I diabetes, suggesting that it imparts a
fundamental autoimmune diathesis [82].
One possibility is that the attenuation of TCR signaling by the
Lyp R620W mutant may lead to a selection shift in thymic
development, favoring the generation in the periphery of a
repertoire of high-avidity autoreactive T cells. This hypothesis
would certainly be in keeping with observations made in the
SKG mouse, a model of spontaneous autoimmune inflam-
matory arthritis that arises through a point mutation in the
protein tyrosine kinase ZAP-70 [83]. In this model there is
clear evidence of a thymic selection shift in favor of
autoreactive T cells, which - in spite of impaired TCR signals -
proliferate vigourously in vivo in response to self antigen/MHC
complexes and differentiate into Th17 effector T cells [84].
Impaired function of both human Lyp R620W and mouse
SKG regulatory T cells has also been proposed to contribute
to the autoimmune diathesis, through similar mechanisms
relating to TCR signaling defects. Data to date are sparse, but
one recent study [85] confirmed that PTPN22 1858T carriers
make less IL-2 and IL-10 in response to TCR stimulation,
whereas TNF-α and IFN-γ are spared. Interestingly, the
number of memory CD4+ T cells is also expanded, which
might arise as a direct consequence of enhanced self
reactivity. It remains to be determined whether this mutation
imposes a distinct T-cell phenotype, or whether the function of
B cells, NK cells, and/or dendritic cells is also affected.
Conclusion
RA is perhaps best described as a prototype chronic
inflammatory disease with features of autoimmunity. The
target of autoreactivity remains unclear, but emerging data
suggest that in RA there are immune reactions to inflam-
mation arising as a consequence of tissue damage and cell
death, a process that is clearly dependent on aging and
immune senescence. There exist both acquired and inherited
defects in  antigen receptor signaling that probably have
impacts on both central thymic and peripheral pathways of
tolerance. In the inflamed synovial joint, persistence is probably
mediated more through over-exuberant co-stimulatory pathways
in T cells than through conventional pathways of antigen-
specific activation. Clearly, this has implications for therapy,
and may explain why the more selective approaches for
targeting adaptive immunity have been more successful than
those based on more conventional immunosuppression.
Because we now have the tools to define disease subtypes
at the tissue, cellular, and molecular levels, patient-tailored
therapy could soon be a reality.
Available online http://arthritis-research.com/supplements/10/S1/S1
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Key messages
￿ Our understanding of the phenotype and function of
RA peripheral blood and synovial T cells points to a
key role for inflammation and aging in the
pathogenic process.
￿ Extensive phenotypic analysis has defined a number
of cell surface molecules that can be exploited for
therapeutic purposes, including co-stimulatory
molecules.
￿ The antigenic determinants recognized by
autoreactive T cells remain poorly defined in RA.
However, a growing appreciation of the specificity
of serum autoantibodies is likely to underpin
attempts to define the relevant pathogenic antigen
reactive T cell clones in the near future.
￿ T-cell effector pathways in RA are complex. The
precise role and contribution of Th1 and Th17
T cells, and how they contribute to the chronicity of
the inflammatory process, remain to be determined.
￿ More detailed phenotypic analysis and
characterisation of regulatory T cell subsets are
required in RA to determine whether any functional
deficiencies reside in the Treg or responding
T effector cell populations (or both).
￿ Advances in defining genetic susceptibility to RA
suggest that aberrant pathways of T-cell activation,
differentiation, and persistence are key. Apart from
HLA-DRB1, disease-associated variants include
PTPN22, CTLA4, IL2RA, IL2RB, and STAT4.Competing interests
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